On December 16, 2025, MAIA Biotechnology, Inc. entered into definitive agreements for a private placement of 1,233,488 shares of common stock at a purchase price of $1.224 per share, generating approximately $1.51 million in gross proceeds before offering expenses. The transaction is expected to close on or about December 18, 2025.
Net proceeds will be allocated to fund Step 1 of Part C of the Phase II THIO‑101 trial and to support general working capital needs. The financing is intended to extend the company’s cash runway as it continues to advance its lead telomere‑targeting asset, ateganosine (THIO), through clinical development.
MAIA’s cash balance stood at $10.9 million and its average quarterly burn was roughly $3.9 million. The $1.51 million infusion raises total liquidity to about $12.4 million, extending the runway to just over three months at the current burn rate and providing a buffer for the next clinical milestone.
CEO Vlad Vitoc emphasized the significance of the trial expansion, noting that ateganosine’s observed overall survival of 17.8 months in third‑line non‑small‑cell lung cancer exceeds standard‑of‑care benchmarks. He added that the company’s Fast Track designation and positive data position it for a potential first‑mover advantage in a multibillion‑dollar market.
The private placement also includes warrants to purchase shares at $1.36, exercisable six months after issuance and expiring three years later. The company has previously secured a $2.3 million NIH grant for the THIO‑101 Phase 2 trial and has seen insider buying by leadership, underscoring confidence in the platform.
For a clinical‑stage biotech with no revenue, the financing represents a critical capital‑raising event that underpins the company’s ability to reach the next development milestone. The additional liquidity, combined with the company’s clinical momentum, positions MAIA to pursue further expansion of the ateganosine program and to maintain operational flexibility in a competitive oncology landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.